Clinical Intelligence/Clinical Efficiency

Insilico Medicine Announces an PROTAC R&D Collaboration with Arvinas

Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine’s AI-augmented platforms and close cooperation between Arvinas’ and Insilico Medicine’s scientists on novel PROTACs. The collaboration will include the design of transformative treatment modalities for existing and next-generation targets; and demonstrate the impact of combining AI with one of the most significant breakthrough technologies in drug discovery – PROTACs.

“Arvinas is the pioneer of PROTAC technology and a leader in protein degradation therapeutics. We look forward to collaborating with Arvinas in this innovative field and to building a lasting relationship,” said Alex Zhavoronkov Ph.D., CEO of Insilico Medicine.

In July the company announced the completion of a $255 million round led by Warburg Pincus and joined by over 25 high-profile investors, and in August,  it nominated the second preclinical candidate for kidney fibrosis.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to

Related posts

Clinical Intelligence Co. Pfizer Announces Investor Relations Leader

Business Wire

Clinical Intelligence Leader Inteliquet™ Highlights RWD Analysis

PR Newswire

ViAqua Therapeutics Announces $4.3 Million Investment

PR Newswire